Bio-Path Holdings, Inc. announced the formation of its inaugural Scientific Advisory Board comprised of oncology experts. Jorge Cortes, M.D., leukemia expert from The University of Texas MD Anderson Cancer Center, will join as Chairman, where he will provide clinical and scientific guidance, and work with Bio-Path to identify and attract additional oncology thought leaders to join the company's growing Scientific Advisory Board. Amy P. Sing, M.D., a member of Bio-Path's board of directors and Senior Director of Medical Affairs at Genomic Health, Inc., will also join a founding member.

Dr. Cortes joins Bio-Path's Scientific Advisory Board as a expert in oncology and hematology. He currently holds several positions at The University of Texas MD Anderson Cancer Center, including Jane and John Justin Distinguished Chair in Leukemia Research, Chief of the AML (acute myeloid leukemia) and CML (chronic myelogenous leukemia) sections, and Deputy Chair of the Department of Leukemia. Dr. Sing joins the Scientific Advisory Board as a member of Bio-Path's board of directors, where she has served since November 2014.

She is the Senior Director of Medical Affairs at Genomic Health, Inc. Dr. Sing has more than 20 years of experience working in the oncology space in various roles. Earlier in her career, she served as Senior Medical Director at Genentech, Inc., where she played an integral role in the Avastin program. Earlier, Dr. Sing served as the Senior Director of Medical and Regulatory Affairs at Seattle Genetics, at which she managed clinical programs for the company's various antibody drug conjugates for the treatment of cancers.